Case Report: Acute liver injury with Epstein-Barr virus DNAemia following teplizumab: drug-induced liver injury, viral reactivation, or both?
Frontiers in Endocrinology · 29.10.2026 · 17
DOI: 10.3389/fendo.2026.2008253 ↗Kurz gefasst
Fallbericht in der Zeitschrift Frontiers in Endocrinology, online erschienen am 29.10.2026. Verfasst von Luca Zagaroli und 13 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Pediatrics, San Salvatore Hospital, L'Aquila, Italy. Hauptthemen laut MEDLINE: Herpesvirus 4, Human, Epstein-Barr Virus Infections, Chemical and Drug Induced Liver Injury, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Teplizumab (anti-CD3) delays progression from stage 2 to stage 3 type 1 diabetes (T1D) but can be associated with laboratory abnormalities and virologic findings, including Epstein-Barr virus (EBV) DNAemia.
Methods
We report a 15-year-old boy with stage 2 T1D who received a standard course of teplizumab and developed a biphasic rise in aminotransferases occurring mainly after the end of infusions, with preserved bilirubin and coagulation parameters.
Results
During treatment, ALT/AST rose to 78/44 U/L (1.90/1.10×ULN). After completion, ALT/AST increased to 292/172 U/L (7.12/4.30×ULN) on post-treatment day +5 and peaked at 428/220 U/L (10.44/5.50×ULN) on day +6, followed by partial improvement and a second flare beginning on day +20 and peaking on day +24 (ALT 293 U/L, 7.15×ULN; AST 118 U/L, 2.95×ULN; GGT 142 U/L), with normal bilirubin. Coagulation parameters remained within the normal range. Work-up for autoimmune hepatitis, hepatitis B/C, CMV, adenovirus, parvovirus B19, and toxoplasmosis was negative. Abdominal ultrasound/Doppler was unremarkable. MRI reported liver size mildly increased/at the upper limit of normal, nonspecific segment IV abnormalities, and reactive abdominal lymph nodes, with interval improvement at follow-up. Pre-treatment VCA IgG was positive and VCA IgM negative. At post-treatment day +10, whole-blood EBV DNA was 538,623 copies/mL, with negative VCA IgM, EA IgG and EBNA IgG, decreasing to <200 copies/mL at 6 months. Liver enzymes normalized spontaneously over follow-up.
Conclusion
This case highlights marked, biphasic liver injury occurring after teplizumab in association with marked EBV DNAemia. The available clinical, serological, virological, and medication-timing data do not permit definitive attribution to teplizumab, EBV-related hepatic involvement, or concomitant medications. Post-treatment monitoring of both liver enzymes and EBV DNA may be helpful.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Pediatrics, San Salvatore Hospital, L'Aquila, Italy.
- Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
- Dietetics Service, San Salvatore Hospital, L'Aquila, Italy.
Zitieren
APA
Zagaroli, L., Cattivera, V., Guerra, F., Zara, S., Iezzi, M. L., Bottone, G., Caloisi, C., Fabiano, C., Gentile, C., Iapadre, G., Nanni, G., Palumbo, L., Salpietro, V., & Delvecchio, M. (2026). Case Report: Acute liver injury with Epstein-Barr virus DNAemia following teplizumab: drug-induced liver injury, viral reactivation, or both?. Frontiers in Endocrinology, 17. https://doi.org/10.3389/fendo.2026.2008253
Vancouver
Zagaroli L, Cattivera V, Guerra F, Zara S, Iezzi ML, Bottone G, et al. Case Report: Acute liver injury with Epstein-Barr virus DNAemia following teplizumab: drug-induced liver injury, viral reactivation, or both?. Frontiers in Endocrinology. 2026;17. doi:10.3389/fendo.2026.2008253
BibTeX
@article{Zagaroli2026,
author = {Zagaroli, Luca and Cattivera, Valentina and Guerra, Federica and Zara, Sabina and Iezzi, Maria Laura and Bottone, Gabriella and Caloisi, Claudia and Fabiano, Cecilia and Gentile, Cristina and Iapadre, Giulia and Nanni, Giuliana and Palumbo, Laura and Salpietro, Vincenzo and Delvecchio, Maurizio},
title = {Case Report: Acute liver injury with Epstein-Barr virus DNAemia following teplizumab: drug-induced liver injury, viral reactivation, or both?},
journal = {Frontiers in Endocrinology},
year = {2026},
volume = {17},
doi = {10.3389/fendo.2026.2008253}
}
EUVIMED